Chemomab TherapeuticsCMMB
13F holders, Q2 2025 (June 30)14holders −3
2new positions
5sold out
$1.16avg. 13F price*
At the end of Q2 2025, 14 institutions reported holding Chemomab Therapeutics Ltd. (CMMB) in their 13F filings, down 3 from Q1 2025. 2 opened new positions and 5 sold out. The largest holders were Morgan Stanley ($1.9M), Orbimed Advisors LLC ($1.1M) and Sphera Funds Management LTD. ($856K).
- Company
- Chemomab Therapeutics Ltd.
- CUSIP
- 16385C104
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $25K |
| Exits | 5 | $85K |
All 13F filers, Q1 2025 → Q2 2025: 1,539,939 shares bought and 1,040,830 shares sold, net +499,109 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 14 holders
| Morgan Stanley | 0.00% | Add +1277.7% | 1,614,134 | $1.9M |
| Orbimed Advisors LLC | 0.03% | Reduce -46.0% | 940,990 | $1.1M |
| Sphera Funds Management LTD. | 0.22% | Reduce -18.0% | 738,048 | $856K |
| Yelin Lapidot Holdings Management Ltd. | 0.12% | No change | 578,291 | $671K |
| Ikarian Capital, LLC | 0.08% | No change | 213,052 | $247K |
| Rhumbline Advisers | 0.00% | Add +67.2% | 39,875 | $46K |
| Kestra Private Wealth Services, LLC | 0.00% | No change | 31,241 | $36K |
| Boothbay Fund Management, LLC | 0.00% | No change | 26,189 | $30K |
| Jane Street Group, LLC | 0.00% | New | 20,569 | $24K |
| BNP Paribas Financial Markets | 0.00% | Add +32.4% | 13,900 | $16K |
| GAMMA Investing LLC | 0.00% | Add +16.2% | 12,811 | $15K |
| JPMorgan Chase & Co. | 0.00% | New | 1,180 | $1K |
| UBS Group AG | 0.00% | Reduce -55.0% | 397 | $461 |
| SBI Securities Co., Ltd. | 0.00% | Add +6.7% | 111 | $129 |
"% of holder's portfolio" is CMMB's weight in each manager's 13F, not the share of Chemomab Therapeutics Ltd. the manager owns.